DE60207550D1 - Tripeptidderivate zur behandlung von postläsionalen krankheiten des nervensystems - Google Patents

Tripeptidderivate zur behandlung von postläsionalen krankheiten des nervensystems

Info

Publication number
DE60207550D1
DE60207550D1 DE60207550T DE60207550T DE60207550D1 DE 60207550 D1 DE60207550 D1 DE 60207550D1 DE 60207550 T DE60207550 T DE 60207550T DE 60207550 T DE60207550 T DE 60207550T DE 60207550 D1 DE60207550 D1 DE 60207550D1
Authority
DE
Germany
Prior art keywords
sub
alkoxy
alkyl
treatment
residue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60207550T
Other languages
English (en)
Other versions
DE60207550T2 (de
Inventor
Jean Rapin
Klaus Witzmann
Jean-Marie Grumel
Jacques Gonella
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NEUROTELL AG HERGISWIL
Original Assignee
NEUROTELL AG HERGISWIL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NEUROTELL AG HERGISWIL filed Critical NEUROTELL AG HERGISWIL
Priority to DE60207550T priority Critical patent/DE60207550T2/de
Application granted granted Critical
Publication of DE60207550D1 publication Critical patent/DE60207550D1/de
Publication of DE60207550T2 publication Critical patent/DE60207550T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DE60207550T 2001-02-05 2002-02-05 Tripeptidderivate zur behandlung von postläsionalen krankheiten des nervensystems Expired - Lifetime DE60207550T2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE60207550T DE60207550T2 (de) 2001-02-05 2002-02-05 Tripeptidderivate zur behandlung von postläsionalen krankheiten des nervensystems

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10105040 2001-02-05
DE10105040A DE10105040A1 (de) 2001-02-05 2001-02-05 Tripeptid-Derivate für die Behandlung von postläsionalen Krankheiten des Nervensystems
PCT/EP2002/001182 WO2002062372A2 (en) 2001-02-05 2002-02-05 Tripeptide derivatives for the treatment of postlesional diseases of the nervous system
DE60207550T DE60207550T2 (de) 2001-02-05 2002-02-05 Tripeptidderivate zur behandlung von postläsionalen krankheiten des nervensystems

Publications (2)

Publication Number Publication Date
DE60207550D1 true DE60207550D1 (de) 2005-12-29
DE60207550T2 DE60207550T2 (de) 2006-08-10

Family

ID=7672833

Family Applications (2)

Application Number Title Priority Date Filing Date
DE10105040A Ceased DE10105040A1 (de) 2001-02-05 2001-02-05 Tripeptid-Derivate für die Behandlung von postläsionalen Krankheiten des Nervensystems
DE60207550T Expired - Lifetime DE60207550T2 (de) 2001-02-05 2002-02-05 Tripeptidderivate zur behandlung von postläsionalen krankheiten des nervensystems

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE10105040A Ceased DE10105040A1 (de) 2001-02-05 2001-02-05 Tripeptid-Derivate für die Behandlung von postläsionalen Krankheiten des Nervensystems

Country Status (9)

Country Link
US (1) US7163922B2 (de)
EP (1) EP1390055B1 (de)
JP (1) JP2004526701A (de)
AT (1) ATE310529T1 (de)
AU (1) AU2002238532A1 (de)
DE (2) DE10105040A1 (de)
DK (1) DK1390055T3 (de)
ES (1) ES2250617T3 (de)
WO (1) WO2002062372A2 (de)

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3864124D1 (de) * 1987-05-20 1991-09-12 Zambon Spa Isoxazole mit nootropischer wirkung.
CA1323301C (en) 1987-06-05 1993-10-19 Alan I. Faden Thyrotropin-releasing hormone analogs in cns injury
FR2622581B1 (fr) * 1987-11-03 1990-02-16 Inorgan Sa Rech Develop Pharm Nouveaux derives de l-proline, leur preparation et leurs applications biologiques
HU904967D0 (en) * 1988-04-22 1991-01-28 Hoechst Ag Process for producing new azabicyclo(3.3.o)octane-3-carboxylic acid-octylesther derivatives
DE4007869A1 (de) 1990-03-13 1991-09-19 Merck Patent Gmbh Aminosaeurederivate
JPH045240A (ja) 1990-04-20 1992-01-09 Taisho Pharmaceut Co Ltd 抗痴呆剤
CA2098609A1 (en) 1990-12-28 1992-06-29 Raymond T. Bartus Use of calpain inhibitors in the inhibition and treatment of neurodegeneration
WO1992013549A1 (en) * 1991-02-07 1992-08-20 Research Corporation Technologies, Inc. Inhibition of cell proliferation by hydrophobic peptides
US6235929B1 (en) 1991-12-27 2001-05-22 Georgia Tech Research Corporation Tripeptide α-ketoamides
US5716929A (en) 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5834029A (en) 1994-07-20 1998-11-10 Cytotherapeutics, Inc. Nerve guidance channel containing bioartificial three-dimensional hydrogel extracellular matrix derivatized with cell adhesive peptide fragment
WO1996041638A1 (en) 1995-06-13 1996-12-27 Sanofi Winthrop, Inc. Calpain inhibitors for the treatment of neurodegenerative diseases
US5840838A (en) * 1996-02-29 1998-11-24 University Of Kentucky Research Foundation Process for enhancing the activity of amyloid β peptides
EP0929313A4 (de) 1996-10-04 2004-04-21 Auckland Uniservices Ltd Regulation neuraler enzyme
JP4727770B2 (ja) * 1997-09-26 2011-07-20 カルピス株式会社 尿中カテコールアミン低下、尿中ノルアドレナリン低下、尿中ドーパミン低下及びＦｉｓｃｈｅｒ比低下の少なくとも１つの軽減剤
US6080848A (en) * 1998-05-01 2000-06-27 Incyte Pharmaceuticals, Inc. Human brain associated protein
US6379691B1 (en) * 1998-09-29 2002-04-30 Medtronic/Ave, Inc. Uses for medical devices having a lubricious, nitric oxide-releasing coating
WO2001028578A2 (en) * 1999-10-22 2001-04-26 Wrair A PHARMACEUTICAL COMPOSITION CONTAINING pGLU-GLU-PRO-NH2 AND METHOD FOR TREATING DISEASES AND INJURIES TO THE BRAIN, SPINAL CORD AND RETINA USING SAME
JP4633876B2 (ja) 1999-11-11 2011-02-16 カルピス株式会社 トリペプチドの製造方法
WO2001068114A1 (en) 2000-03-10 2001-09-20 Monsanto Company Novel peptides with anti-hypertensive activity
DE10105041A1 (de) * 2001-02-05 2002-08-14 Tell Pharm Ag Hergiswil Tripeptide und Tripeptid-Derivate für die Behandlung neurodegenerativer Krankheiten
DE10105038B4 (de) * 2001-02-05 2005-07-07 Neurotell Ag Tripeptid-Derivate für die Behandlung von postläsionalen Krankheiten des Nervensystems

Also Published As

Publication number Publication date
ES2250617T3 (es) 2006-04-16
DE60207550T2 (de) 2006-08-10
EP1390055A2 (de) 2004-02-25
US20050101539A1 (en) 2005-05-12
WO2002062372A2 (en) 2002-08-15
DK1390055T3 (da) 2006-01-09
DE10105040A1 (de) 2002-08-14
AU2002238532A1 (en) 2002-08-19
US7163922B2 (en) 2007-01-16
WO2002062372A3 (en) 2004-01-08
JP2004526701A (ja) 2004-09-02
ATE310529T1 (de) 2005-12-15
EP1390055B1 (de) 2005-11-23

Similar Documents

Publication Publication Date Title
CY1107990T1 (el) Τριπεπτιδια και παραγωγα τριπεπτιδιων για τη θepαπεια νευροεκφυλιστικων ασθενειων
HUP0000492A1 (hu) N-(Aril/heteroaril-acetil)-aminosav-észterek, azokat tartalmazó gyógyászati készítmények, valamint módszerek béta-amiloid fehérje képződése és felszabadulása gátlására e vegyületek felhasználásával
MY146669A (en) Pyrazole derivatives for treating hiv
RO115355B1 (ro) Derivati de aminoacizi
DE59007517D1 (de) Neue proteine mit tnf-hemmender wirkung und ihre herstellung.
TNSN00256A1 (fr) Inhibiteurs non peptidiques de la liaison cellulaire sous la dependance de vla-4 utiles dans le traitement des maladies inflammatoires, auto-immunes et respiratoires, et compositions les contenant
TNSN04017A1 (en) N-(3-amino-2-hydroxy-propyl) substituted alkylamide compounds
AU6999796A (en) Heterocyclic compounds as bradykinin antagonists
BR0012418A (pt) Derivados de peptìdeo cìclicos como inibidores de integrina alfavbeta6
BR0115424A (pt) Composto, composição farmacêutica, métodos para inibir a liberação de peptìdeo beta-amilóide e/ou sua sìntese, para tratar a doença de alzheimer, para prevenir a doença de alzheimer, e para inibir o progresso da doença de alzheimer, processos para preparar o composto, e para preparar lactamas, e, uso do composto
DE60318874D1 (en) Pyrazolderivate
WO2002024213A3 (en) Improved protocol for paracentesis
DE60202356D1 (de) Tripeptide und deren derivate zur behandlung von postläsionalen krankheiten des nervensystems
DE60207550D1 (de) Tripeptidderivate zur behandlung von postläsionalen krankheiten des nervensystems
EA200400603A1 (ru) Новые пептиды - аналоги гормона высвобождения гормона роста человека
EP1908781A3 (de) Modulation der Immunreaktion und darauf basierende Verfahren
NZ519062A (en) Peptides for treatment of erectile dysfunction
DE60319254D1 (de) Pyrazolamide zur behandlung von hiv-infektionen
DE60137340D1 (de) Inhibitoren von hiv-replikation und verfahren zur behandlung einer der von hiv verursachten infektionen
WO2002083729A3 (en) Polypeptides derived from amyloid precursor peptide (app) and their uses
GB0223234D0 (en) Chemical compounds
DE60034580D1 (de) Peptid zur behandlung von nervenerkrankungen
DE69813232T2 (de) Wespe pompilid neuropeptide
HUP0300083A2 (hu) Készítmény immunszupresszív szerek alkalmazása által indukált citotoxikus hatások kezelésére és/vagy megelőzésére
UY25369A1 (es) Procedimiento para preparar inhibidores de proteasa

Legal Events

Date Code Title Description
8364 No opposition during term of opposition